Pramipexole Dihydrochloride

【药融CDMO之家】CDMO/CMO 专属供需平台，涵盖生产外包、工艺技术、中试及商业化合作，助力 MAH 与生产型 CXO 精准共赢！ 今日供需对接 排序 药品名称 药品适应症大类 1 马来酸氯苯那敏片 呼吸系统药物 2 地氯雷他定片 呼吸系统药物3 氯芬黄敏片 呼吸系统药物4 富马酸卢帕他定片 呼吸系统药物5 美洛昔康片 肌肉-骨骼系统药物6 依托考昔片 肌肉-骨骼系统药物7 硫酸软骨素钠片 肌肉-骨骼系统药物8 萘普生钠片 肌肉-骨骼系统用药9 阿帕他胺片 抗肿瘤药和免疫机能调节药物10 磷酸芦可替尼片 抗肿瘤药和免疫机能调节药物11 依西美坦片 抗肿瘤药物和免疫机能调节药物12 醋酸阿比特龙片 抗肿瘤药物和免疫机能调节药物13 枸橼酸托法替布片 抗肿瘤药物和免疫机能调节药物14 艾拉莫德片 抗肿瘤药物和免疫机能调节药物15 盐酸西那卡塞片 全身用激素类制剂(不含性激素和胰岛素)16 氢溴酸伏硫西汀片 神经系统药物17 阿立哌唑片 神经系统药物18 氨磺必利片 神经系统药物19 盐酸帕罗西汀片 神经系统药物20 拉考沙胺片 神经系统药物21 马来酸氟伏沙明片 神经系统药物22 盐酸帕罗西汀肠溶缓释片 神经系统药物23 富马酸喹硫平片 神经系统药物24 盐酸美金刚片 神经系统药物 25 盐酸鲁拉西酮片 神经系统药物26 多巴丝肼片 神经系统药物27 盐酸普拉克索缓释片 神经系统用药28 左乙拉西坦缓释片 神经系统用药29 门冬酰胺片 生殖泌尿系统和性激素类药物30 枸橼酸西地那非口崩片 生殖泌尿系统和性激素类药物31 他达拉非片 生殖泌尿系统和性激素类药物32 富马酸替诺福韦二吡呋酯片 系统用抗感染药物33 恩曲他滨替诺福韦片 系统用抗感染药物34 索磷布韦片 系统用抗感染药物35 玛巴洛沙韦片 系统用抗感染药物36 复方磺胺甲噁唑片 系统用抗感染药物37 琥乙红霉素片 系统用抗感染药物38 恩格列净二甲双胍缓释片（IV） 消化系统与代谢药物39 恩格列净二甲双胍缓释片（III） 消化系统与代谢药物40 恩格列净二甲双胍缓释片（II） 消化系统与代谢药物41 恩格列净二甲双胍缓释片（I） 消化系统与代谢药物42 阿卡波糖片 消化系统与代谢药物43 苯甲酸阿格列汀片 消化系统与代谢药物44 二甲双胍格列本脲片(Ⅰ) 消化系统与代谢药物45 维格列汀片 消化系统与代谢药物46 琥珀酸普芦卡必利片 消化系统与代谢药物47 铝碳酸镁咀嚼片 消化系统与代谢药物48 那格列奈片 消化系统与代谢药物49 维生素C泡腾片 消化系统与代谢药物50 维生素C片 消化系统与代谢药物51 马来酸氨氯地平片 心血管系统药物52 复方芦丁片 心血管系统药物53 奥美沙坦酯氨氯地平片 心血管系统药物54 阿替洛尔片 心血管系统药物55 替米沙坦氨氯地平片 心血管系统药物56 盐酸乐卡地平片 心血管系统药物57 富马酸比索洛尔片 心血管系统药物58 尼麦角林片 心血管系统药物59 阿托伐他汀钙片 心血管系统药物60 缬沙坦氨氯地平片(Ⅰ) 心血管系统药物61 氨氯地平阿托伐他汀钙片 心血管系统药物62 硝苯地平控释片 心血管系统用药63 阿哌沙班片 血液和造血系统药物64 马来酸阿伐曲泊帕片 血液和造血系统药物65 叶酸片 血液和造血系统药物66 硫酸氢氯吡格雷片 血液和造血系统药物67 贝前列素钠片 血液和造血系统药物68 替格瑞洛片 血液和造血系统药物 你是否有这样的无力感？ 看着集采目录越来越密，利润薄得像纸； 手里批文一堆，能打的却没几个； 想转型高壁垒，研发投入大、周期长、风险高； 出去找品种，约不到关键人、谈不深、敲不定…… 仿制药企业的核心痛点，从来不是“要不要做”，而是“拿什么做”。 好品种，才是命根子。 第八届CMC药博会 中国制药工业全产业链生态大会专设「仿制药品种交易专场」 我们不搞虚的，只做一件事—— //////////////////// HOT 扫码立即报名 首仿、高壁垒、复杂制剂、特色原料药…… 总有一款，补齐你的管线缺口。 来自全国的主流仿制药企、MAH持证人、研发型CRO，带着已获批/即将获批/可转让的成熟品种，现场设展、直面沟通。不是画饼，不是PPT，是真实可交易的品种池。 不是画饼，不是PPT，是真实可交易的品种池。 不是递名片，是坐下来深谈 代理、转让、联合开发、股权合作…… 模式灵活，利益共享。 我们定向邀请有决策权的企业一把手/研发负责人/BD负责人到场， 不谈虚的，只聊合作细节。 在找品种之前，先找准方向—— 复杂制剂怎么做才有壁垒？ 哪些细分赛道还有集采红利？ 改良型新药的3年保护期怎么用？ 首仿药的申报策略与时间窗口如何卡位？ D馆·仿制药与改良新药系列论坛，中国药科大专家、前CDE审评员、一线企业实战派，帮你看清趋势，再做决策。 HOT !  HOT！ CMC-CHINA 同期重磅活动 一票通享 D105 药品批文项目交易大会：批文转让+招商代理，一站式对接 D106 对话工业药企决策层：30+企业家观点碰撞，2026年仿制药还能怎么玩？ E103 委托生产与质量合规论坛：MAH制度下的B证/C证合作全攻略 获取高清大图/参展联系15968101495 刘经理   点击图片或扫描二维码了解详情↓↓

– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 – – Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges' g=0.62, p=0.006) – – Approximately $100 million financing completed in July 2026; pro forma cash of approximately $338 million expected to fund planned operations through 2030 – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- $anro #cns --Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “The Nature Medicine publication of PRIME-PRAXOL provides another independent, peer-reviewed dataset showing that dopaminergic treatment produces large effects in depression, and, just as importantly, a reminder of the tolerability challenge that ALTO-207 is designed to address. With enrollment in our potentially registrational Phase 2b trial tracking as planned and pro forma cash of approximately $338 million, we are now positioned to pursue ALTO-207 in both the adjunctive and monotherapy settings, broadening the potential label and the commercial opportunity, with expected runway through 2030.” Second Quarter and Recent Pipeline Highlights ALTO-207: Independent Nature Medicine publication reinforces mechanism; monotherapy Phase 3 trial added to development plan ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effect across multiple independent trials, and ondansetron, a selective 5-HT3 receptor antagonist. The fixed-dose combination is designed to enable rapid titration to higher pramipexole doses by mitigating the dose-limiting nausea and vomiting associated with pramipexole. This combination approach — and its use to enable higher pramipexole dosing in the treatment of depression — is the subject of Alto's issued method-of-treatment patent estate described below. ALTO-207 is being developed to address the significant unmet medical need in TRD, which is estimated to affect approximately 7 million adults in the United States. In June 2026, results from PRIME-PRAXOL — an independent, randomized, double-blind, placebo-controlled trial conducted by investigators at Lund University, Sweden — were published in Nature Medicine. Adults with major depressive disorder (MDD), dysthymia, or bipolar depression and clinically significant anhedonia received flexible-dose pramipexole or placebo added to ongoing treatment for nine weeks, followed by a six-month open-label extension. The trial met its primary endpoint, with pramipexole reducing anhedonia significantly more than placebo on the Snaith–Hamilton Pleasure Scale (SHAPS) (mean difference −4.04; 95% CI −6.89 to −1.18; p=0.006; Hedges' g=0.62). Significant improvements were also observed on independent measures of anhedonia (DARS; p=0.008) and apathy (AES-S; p<0.001), and improvements were maintained through the six-month open-label period. In an exploratory analysis included in the publication, an MDD diagnosis was significantly associated with greater SHAPS improvement at week 9 relative to dysthymia (p=0.038). In an additional analysis of the trial data not included in the publication, the MDD subgroup showed a larger effect on SHAPS at week 9 (Hedges' g=0.99) and a larger effect on the Hamilton Depression Rating Scale (HDRS-6) (Hedges' g=0.64). Consistent with prior studies, adverse events were common in the pramipexole arm despite slow titration, including nausea in approximately 60% of participants — the dose-limiting tolerability constraint that the ALTO-207 fixed-dose combination is designed to address. These findings are consistent with the broader body of evidence supporting ALTO-207, including the PAX-D study conducted by the University of Oxford and published in The Lancet Psychiatry (Cohen's d=0.87 versus placebo at 12 weeks in TRD) and a meta-analysis of pramipexole in depression (Hedges' g=0.64, p<0.001). The broad development program for ALTO-207, collectively the PACE program ( P ramipexole-ondansetron A ssessment of C linical E fficacy in depression), remains on track across three large, well-controlled clinical trials; PACE-1 Trial (Phase 2b adjunctive TRD trial): Enrollment in the ongoing, potentially registrational, Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD is on track with topline data expected in 2H 2027. MADRS is the primary endpoint in the trial, which is aligned with FDA standards in depression and supports the potential for the trial to contribute to a future registrational package alongside the planned Phase 3 trials. PACE-2 Trial (Phase 3 adjunctive TRD trial): Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial design. The Phase 3 trial is designed to run in parallel with the ongoing Phase 2b trial rather than await its topline data, an approach Alto believes can meaningfully accelerate the path to a potential NDA submission. PACE-3 Trial (Phase 3 monotherapy TRD trial): In July 2026, Alto announced plans to accelerate and expand the clinical development of ALTO-207, including an additional planned Phase 3 trial evaluating ALTO-207 as monotherapy in TRD. The Company believes a monotherapy dataset, alongside the planned adjunctive Phase 3 trial, could support a broader label and expand the addressable population for ALTO-207 if approved. Alto expects to initiate this trial in the second half of 2027 pending alignment with the FDA. Alto's patent estate covering ALTO-207 includes multiple method-of-treatment patents protecting the use of ondansetron to mitigate pramipexole-related side effects to enable higher pramipexole dosing in the treatment of depression. Together with the Company's broader estate of issued and pending patents, Alto expects patent coverage of ALTO-207 through at least the mid-2040s. ALTO-300 and ALTO-100: Phase 2b trials on track Enrollment remains ongoing in the Phase 2b trials of ALTO-300 in MDD and ALTO-100 in bipolar depression (BPD), conducted under the enhanced eligibility review and patient data quality procedures the Company implemented earlier this year, which continue to perform as intended. Topline data remain expected in 1H 2027 for the ALTO-300 Phase 2b MDD trial and mid-2027 for the ALTO-100 Phase 2b BPD trial. Corporate Highlights In July 2026, Alto completed an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, for gross proceeds of approximately $100.0 million and net proceeds of approximately $94.6 million. The Company intends to use the proceeds, together with existing cash, to accelerate and expand the clinical development of ALTO-207, including the additional planned Phase 3 monotherapy trial in TRD, and for general working capital purposes. In June 2026, Alto was added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective June 29, 2026, as part of the 2026 Russell US Indexes reconstitution. In May 2026, Alto appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors. During his tenure, Dr. Miller was CEO, COO, and led research and development at Karuna through its acquisition by Bristol Myers Squibb, and brings extensive neuropsychiatric drug development and company-building experience to Alto. Expected Upcoming Milestones Early 2027 — ALTO-207 PACE-2 (Phase 3 adjunctive TRD) trial initiation 1H 2027 — ALTO-300 Phase 2b MDD trial topline data Mid-2027 — ALTO-100 Phase 2b BPD trial topline data 2H 2027 — ALTO-207 PACE-1 (Phase 2b adjunctive TRD) trial topline data 2H 2027 — ALTO-207 PACE-3 (Phase 3 monotherapy TRD) trial initiation Second Quarter 2026 Financial Highlights Cash Position: As of June 30, 2026, the Company had cash, cash equivalents, and restricted cash of approximately $244.2 million, compared to approximately $177.0 million as of December 31, 2025. Giving effect to the net proceeds of the July 2026 offering, the Company's pro forma cash position following the offering was approximately $338 million. R&D Expenses: Research and development expenses for the quarter ended June 30, 2026, were $22.1 million, as compared to $13.1 million for the same period in 2025. G&A Expenses: General and administrative expenses for the quarter ended June 30, 2026, were $7.0 million, as compared to $5.6 million for the same period in 2025. Net Loss: The Company incurred a net loss of $27.6 million for the quarter ended June 30, 2026, as compared to a net loss of $17.7 million for the same period in 2025. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in treatment-resistant depression, major depressive disorder, bipolar depression, schizophrenia, and other mental health conditions. For more information, visit or follow Alto on X . Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “look forward,” “may,” “on track,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations with regard to the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform (“Platform”); statements regarding patient compliance and the effectiveness of Alto’s clinical trial execution measures, including its eligibility review and patient and data quality procedures, and the impact of those measures on patient and data quality and the timing of trial readouts; statements regarding Alto’s expectations for the design, timing, and results of its Phase 2b and planned Phase 3 trials of ALTO-207; Alto’s expectations with regard to the design and results of its research and development programs and clinical trials, including the timing of enrollment and the timing and availability of data from such trials; Alto’s clinical and regulatory development plans for its product candidates, including the timing or likelihood of regulatory filings and approvals for its product candidates and regulatory alignment; Alto’s business strategy, financial position, including anticipated cash runway, and the sufficiency of its financial resources to fund its operations through expected milestones; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto’s product candidates; the risk that Alto may not realize the intended benefits of its Platform or its eligibility review and patient and data quality procedures; availability and timing of results from clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that clinical trials may have unsatisfactory outcomes; the risk that Alto’s projections regarding its financial position and expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in Alto’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings Alto may make with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Availability of Information on Alto's Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website. ALTO NEUROSCIENCE, INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share amounts) (unaudited) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Operating expenses: Research and development $ 22,108 $ 13,124 $ 42,402 $ 23,098 General and administrative 7,021 5,558 13,865 11,260 Total operating expenses 29,129 18,682 56,267 34,358 Loss from operations (29,129 ) (18,682 ) (56,267 ) (34,358 ) Other income (expense): Interest income 2,112 1,683 3,673 3,510 Interest expense (491 ) (646 ) (1,036 ) (1,244 ) Loss on debt extinguishment — — — (681 ) Other, net (130 ) (61 ) (245 ) (102 ) Total other income, net 1,491 976 2,392 1,483 Net loss $ (27,638 ) $ (17,706 ) $ (53,875 ) $ (32,875 ) Other comprehensive income (loss): Change in fair value attributable to instrument specific credit risk — 22 7 156 Foreign currency translation 4 (5 ) (12 ) (24 ) Total other comprehensive income (loss) $ 4 $ 17 $ (5 ) $ 132 Comprehensive loss $ (27,634 ) $ (17,689 ) $ (53,880 ) $ (32,743 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.65 ) $ (0.65 ) $ (1.34 ) $ (1.21 ) Weighted-average number of common shares outstanding, basic and diluted 42,813 27,072 40,179 27,061 ALTO NEUROSCIENCE, INC. Selected Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) June 30, December 31, 2026 2025 Cash, cash equivalents, and restricted cash $ 244,233 $ 176,984 Total assets 254,066 184,689 Total liabilities 34,817 33,547 Accumulated deficit (255,509 ) (201,634 ) Contacts Investor & Media Contact: Nick Smith investors@altoneuroscience.com media@altoneuroscience.com